Literature DB >> 11520893

Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol.

W Maruyama1, Y Akao, M B Youdim, B A Davis, M Naoi.   

Abstract

An endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, was found to induce apoptosis in human dopaminergic SH-SY5Y cells by step-wise activation of apoptotic cascade; collapse in mitochondrial membrane potential, DeltaPsim, activation of caspases, and fragmentation of DNA. Recently, accumulation of gylceraldehyde-3-phosphate dehydrogenase (GAPDH) in nuclei was proposed to play an important role in apoptosis. In this paper, involvement of GAPDH in apoptosis induced by N-methyl(R)salsolinol was studied. The isoquinoline reduced DeltaPsim within 3 h, as detected by a fluorescence indicator, JC-1, then after 16 h incubation, GAPDH accumulated in nuclei by detection with immunostaining. To clarify the role of GAPDH in apoptotic process, a stable cell line of Bcl-2 overexpressed SH-SY5Y cells was established. Overexpression of Bcl-2 prevented the decline in DeltaPsim and also apoptotic DNA damage induced by N-methyl(R)salsolinol. In Bcl-2 transfected cells, nuclear translocation of GAPDH was also completely suppressed. In addition, a novel antiparkinsonian drug, rasagiline, prevented nuclear accumulation of GAPDH induced by N-methyl(R)salsolinol in control cells. These results suggest that GAPDH may accumulate in nuclei as a consequence of signal transduction, which is antagonized by anti-apoptotic Bcl-2 protein family and rasagiline. The results are discussed in concern to intracellular mechanism underlying anti-apoptotic function of rasagiline analogues.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520893     DOI: 10.1046/j.1471-4159.2001.00448.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  40 in total

Review 1.  Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Authors:  Anthony H V Schapira
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.

Authors:  Zachary Macchi; Yunxia Wang; Dan Moore; Jonathan Katz; David Saperstein; David Walk; Ericka Simpson; Angela Genge; Tulio Bertorini; J Americo Fernandes; Andrea Swenson; Lauren Elman; Mazen Dimachkie; Laura Herbelin; Joann Miller; Jianghua Lu; Heather Wilkins; Russell H Swerdlow; Jeffrey Statland; Richard Barohn
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2015-04-02       Impact factor: 4.092

3.  Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.

Authors:  Keiko Inaba-Hasegawa; Yukihiro Akao; Wakako Maruyama; Makoto Naoi
Journal:  J Neural Transm (Vienna)       Date:  2011-11-08       Impact factor: 3.575

4.  Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.

Authors:  Z Speiser; A Mayk; L Litinetsky; T Fine; A Nyska; E Blaugrund; S Cohen
Journal:  J Neural Transm (Vienna)       Date:  2006-12-21       Impact factor: 3.575

Review 5.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

6.  A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage.

Authors:  Xiao-Ming Ou; Craig A Stockmeier; Herbert Y Meltzer; James C Overholser; George J Jurjus; Lesa Dieter; Kevin Chen; Deyin Lu; Chandra Johnson; Moussa B H Youdim; Mark C Austin; Jia Luo; Akira Sawa; Warren May; Jean C Shih
Journal:  Biol Psychiatry       Date:  2009-12-22       Impact factor: 13.382

Review 7.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

8.  Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.

Authors:  Jeffrey M Statland; Dan Moore; Yunxia Wang; Maureen Walsh; Tahseen Mozaffar; Lauren Elman; Sharon P Nations; Hiroshi Mitsumoto; J Americo Fernandes; David Saperstein; Ghazala Hayat; Laura Herbelin; Chafic Karam; Jonathan Katz; Heather M Wilkins; Abdulbaki Agbas; Russell H Swerdlow; Regina M Santella; Mazen M Dimachkie; Richard J Barohn
Journal:  Muscle Nerve       Date:  2018-11-26       Impact factor: 3.217

9.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

10.  Biological targets for isatin and its analogues: Implications for therapy.

Authors:  Alexei Medvedev; Olga Buneeva; Vivette Glover
Journal:  Biologics       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.